ClinicalTrials.gg
CompletedNCT03694587Updated Apr 16, 2019

pK of a Novel 200 mg Ibuprofen Medicated Plaster

A Phase 1 interventional study of Ibuprofen 200 mg TEPI Medicated Plaster and Aktren® 200 mg überzogene Tabletten (Ibuprofen) in Healthy, sponsored by Medherant Ltd. Completed at 1 site in Bulgaria. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-16.

Sponsored by Medherant Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a Phase I study of the pharmacokinetics of a novel 200 mg Ibuprofen Medicated Plaster. The study will be conducted as a monocentric, open, randomised, single and multiple-dose, two-period, crossover trial in healthy volunteers. A total of 16 healthy volunteers will be randomised.

A wash-out period of 3 days is planned between the two periods. Each of the volunteers will be randomly assigned to one of 2 possible administration sequences.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Medherant Ltd is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subject
  • Age between 18 and 65 years
  • Physically and mentally healthy as judged by means of medical and standard laboratory examinations
  • Non-smokers or ex-smokers (stopped at least 6 months ago) with a smoking history of ≤5 pack-year equivalents (1 pack-year equivalent is equal to smoking 1 pack per day for 1 year**) and non-users of other nicotine containing products, confirmed by urine cotinine test
  • Weight ≥ 60 kg and within the range (including the borders)1 of 18.0 to 30.0 kg/m2
  • given in written form according to chapter 5.4 of the study protocol

Exclusion criteria

Exclusion Criteria:

  • Participation in another clinical trial at same time or within the preceding 90 days (calculated from the date of the final examination of the previous study)
  • Fertile women without reliable method. List of medically accepted contraceptive methods (used at least 4 weeks prior entry screening visit and not to be changed for the duration of the study):
  • combination of 2 barrier methods: female/male condoms, diaphragms, spermicides
  • voluntary sterilization (female tubal occlusion).
  • Randomisation into the present trial more than once
  • Blood donation or blood loss including plasmapheresis of >500 ml in the last 90 days before entry screening
  • Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at entry screening
  • History of drug abuse or use of illegal drugs: use of soft drugs, e.g. marihuana within 6 months of entry screening or hard drugs, e.g. cocaine, amphetamines, phencyclidine within 1 year before entry screening
  • Alcohol abuse, i.e. regular use of more than 2 units of alcohol per day or 10 units per week or a history of alcoholism (one unit of alcohol equals 250 ml beer, 125 ml wine or 25 ml spirits) or recovered alcoholics
  • Regular consumption of beverages or food containing methylxanthines (e.g. coffee, tea, cola, caffeine containing sodas, chocolate) equivalent to more than 500 mg methylxanthines per day
  • Positive drug screening and/or positive alcohol test at entry screening or on hospitalization day -1
  • Pregnant and/or nursing women. Positive pregnancy test at entry screening or on hospitalization day -1
  • Allergic diathesis or any allergic disease (i.e. asthma or bronchial hyperreactivity)
  • Known allergy to sticking plaster or to the ingredients of the products
  • History of or active skin disease or dermatologic disease that might interfere with the evaluation of test site reaction
  • Any history of drug (especially to the active and inactive ingredients of the ibuprofen preparations and NSAIDs including subjects where attacks of asthma, angioedema, urticaria or rhinitis have been precipitated), or intolerance to any sugar (e.g. fructose, glucose, or lactose)
  • History of clinically significant food allergies or current significant or perennial allergy at screening
  • History of disorders such as lupus erythematosus
  • Presence or a history of clinically significant cardiovascular, renal, hepatic, pulmonary, metabolic, endocrine, haematological, gastrointestinal, neurological, psychiatric or other diseases
  • Clinically significant illness within 4 weeks before entry screening and during the study
  • Major surgery of the gastrointestinal tract except for appendectomy
  • Any chronic disease which might interfere with absorption, distribution, metabolism or excretion of the drug
  • Intensive UV-light exposure (sunbaths) at the application site or use of tanning beds within 2 weeks before entry screening and during the study
  • Intake or administration of any systemic or any topical medication (including immune system interfering drugs, OTC medication and especially intake of antacids e.g. aluminum hydroxide, magnesium hydroxide, and simethicone or herbal medication e.g. St. John's wort, kava kava, or use of ointments, gels or patches for skin application, piperine containing products16) as well as hormone replacement therapy within 2 weeks before entry screening and during the study, except single doses of paracetamol given in case of an adverse event (e.g. headache) during the study
  • Use of topical products without medication at the application sites (including make-up, sunscreen, creams, lotions, powders, alcohol) 7 days prior to entry screening until discharge
  • Administration of depot injectable solutions or medications with a half-life > 1 week (including study medications) within 6 months before entry screening
  • Intake of enzyme-inducing, organotoxic or long half-life drugs within 4 weeks before entry screening
  • Medication with drugs known to alter the major organs or systems such as barbiturates, phenothiazines, cimetidine, omeprazole etc. within the last 2 months prior entry screening
  • Any method of hair removal (e.g. waxing, shaving, epilating, laser) at the application sites 7 days prior to entry screening until discharge
  • Subjects with tattoos, sunburn, coloration, open sores or scars (e.g. any burning or stinging) on site(s) of application
  • History of difficulty in swallowing
  • Positive serologic findings for (HIV) antibodies, surface antigen (HBsAg), and/or virus (HCV) antibodies
  • Systolic blood pressure outside the range of 100 to 140 mmHg and/or diastolic blood pressure outside the range of 60 to 90 mmHg17 at entry screening visit
  • Heart rate outside the range of 50 to 90 beats/min at entry screening visit
  • Respiratory rate outside the range of 12-24 breaths/min at entry screening visit
  • Axillary body temperature outside the interval of 35.5 to 37.1°C at entry screening visit
  • Any clinically significant abnormality of the resting (12-lead) (i.e. AV block, 2° to 3°, sinus bradycardia, sick sinus syndrome, SA block)
  • Laboratory values outside normal range with clinical relevance at entry screening visit
  • Vomiting within the first 4 hours after dosing with oral ibuprofen
  • Diarrhoea within the first 24 hours after dosing with oral ibuprofen
  • Special diet due to any reason, e.g. vegetarians
  • Not fulfilling study specific restrictions given in a study protocol
  • Engagement in strenuous exercise within 2 weeks prior to check-in (e.g., marathon runners, weight lifters)
  • Subjects who are known or suspected:
  • not to comply with the study directives
  • not to be reliable or trustworthy
  • not to be capable of understanding and evaluating the information given to them as part of the formal information policy (), in particular regarding the risks and discomfort to which they would agree to be exposed
  • to be in such a precarious financial situation that they no longer weigh up the possible risks of their participation and the inconvenience they may be involved in
  • subject is a dependent person, e.g. a relative, family member, or member of the investigator's or sponsor's staff
  • subject is in custody or submitted to an institution due to a judicial order.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Active comparator
    Test IMP

    Drug: Ibuprofen 200 mg TEPI Medicated Plaster

  • Active comparator
    Reference IMP

    Drug: Aktren® 200 mg überzogene Tabletten (Ibuprofen)

Interventions

06

What researchers measure

Primary outcomes

  1. AUC(0-12h) of ibuprofen

    Area under the concentration/time curve, from time 0 h to 12 h

    Time frame: 5 days

  2. AUC(0-t) of Ibuprofen

    Area under the concentration/time curve, calculated by the trapezoidal rule from time 0 h to last observed concentration at time t

    Time frame: 5 days

  3. Cmax of Ibuprofen

    Observed maximal concentration after administration

    Time frame: 5 days

Secondary outcomes

  1. Tmax after multiple dosing

    Observed time point of maximal concentration

    Time frame: 5 days

  2. t½ after multiple dosing

    Plasma concentration half-life calculated according to t1/2=ln(2)/ λz

    Time frame: 5days

  3. λz of total ibuprofen after multiple dosing

    Terminal rate constant (slowest rate constant of the disposition) negative of the slope of a log-linear regression of the unweighted data considering the last concentration-time points ≥ LLOQ

    Time frame: 5 days

  4. AUC(0-inf) after multiple dosing

    Area under the concentration/time curve, from time 0 h extrapolated to infinity (AUC(0-∞) = AUC(0-t) + Clast/λz where Clast is the last concentration above the limit of quantification and λz is the terminal elimination constant)

    Time frame: 5 days

Other outcomes

  1. AUC(0-τ) After plaster removal,

    Area under the concentration/time curve, from time 0 h the end of the treatment period

    Time frame: 5 days

  2. Number of subjects with product related Adverse Events

    Adverse events from subject informed consent until the follow-up call

    Time frame: 15 days

  3. Change in dermal effect score to baseline

    Skin irritation by using "Dermal Effect Score" and "Other Effect Score") Dermal Response Score Score Definition 0- No evidence of irritation 1. - Minimal erythema, barely perceptible 2. - Definite erythema, readily visible; minimal oedema or minimal papular 3. - Erythema and papules 4. - Definite oedema 5. - Erythema, oedema, and papules 6. - Vesicular eruption 7. - Strong reaction spreading beyond test site Score Definition 0 - None observed 1. - Slight glazed appearance 2. - Marked glazing 3. - Glazing with peeling and cracking 4. - Glazing with fissures. Film of dried serous exudates covering all or part of the patch site Small petechial erosions and/or scabs

    Time frame: 15 days

  4. Abnormal laboratory findings

    Abnormal laboratory findings with respect to the pre-defined reference ranges

    Time frame: 15 days

  5. Adhesion (quantitative, using the mean adhesion score) and qualitative assessment of the plaster

    The percentage of the Ibuprofen 200 mg TEPI plaster adhered to the skin will be assessed at the following time points on application of plaster 1 and plaster 5: at placement of plaster (T0) and then at the following time points post placement: 4, 8, 12, 16, 20 and 24 hours. An adhesion score will be assigned using a 5-point numerical scale 0 = ≥ 90% adhered (essentially no lifting off the skin) 1. = ≥ 75% to \< 90% adhered (some edges only lifting off the skin) 2. = ≥ 50% to \< 75% adhered (less than half of the plaster lifting off the skin) 3. = \> 0% to \< 50% adhered (not detached, but more than half of the plaster lifting off the skin without falling off) 4. = 0% adhered (plaster detached; completely off skin)

    Time frame: Day 1 and Day 5

  6. Cmax, ss after plaster removal

    Observed maximal concentration after administration at steady state

    Time frame: 5 days

  7. CT, ss after plaster removal

    Observed maximal concentration after administration at the end of τ at steady state

    Time frame: 5 days

  8. residual ibuprofen in removed plasters

    Time frame: 5 days

07

Study locations

1 site
  • Clinic of Clinical Pharmacology and Therapeutics University Multidisciplinary Hospital for Active Treatment 'Tsaritsa Ioanna-ISUL' EAD
    Sofia, 1504, Bulgaria
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Oct 2018, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2018
First posted
Oct 3, 2018
StartActual
Sep 25, 2018
Primary completionActual
Oct 18, 2018
CompletionActual
Oct 18, 2018
Last update
Apr 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03694587
Lead sponsor
Medherant Ltd
Collaborators
Cooperative Clinical Drug Research and Development AG (CCDRD AG)
Responsible party
Sponsor
First posted
Oct 3, 2018
Start date
Sep 25, 2018
Primary completion
Oct 18, 2018
Completion
Oct 18, 2018
Last update
Apr 16, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion